Analysts predict that CytomX Therapeutics Inc (NASDAQ:CTMX) will post ($0.55) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have made estimates for CytomX Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.84) and the highest estimate coming in at ($0.29). CytomX Therapeutics posted earnings per share of ($0.72) in the same quarter last year, which would indicate a positive year over year growth rate of 23.6%. The company is scheduled to issue its next quarterly earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that CytomX Therapeutics will report full-year earnings of ($1.96) per share for the current financial year, with EPS estimates ranging from ($2.22) to ($1.76). For the next fiscal year, analysts forecast that the business will report earnings of ($2.46) per share, with EPS estimates ranging from ($2.95) to ($2.10). Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover CytomX Therapeutics.
CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CytomX Therapeutics had a negative net margin of 163.18% and a negative return on equity of 90.62%. The company had revenue of $10.71 million for the quarter, compared to the consensus estimate of $23.58 million.
CTMX stock traded up $0.16 during trading on Friday, reaching $6.29. The company had a trading volume of 283,934 shares, compared to its average volume of 439,568. The company has a debt-to-equity ratio of 0.31, a current ratio of 4.40 and a quick ratio of 4.40. CytomX Therapeutics has a 52 week low of $5.10 and a 52 week high of $19.75. The business has a 50 day moving average of $6.17 and a 200 day moving average of $8.88. The company has a market cap of $285.78 million, a P/E ratio of -3.10 and a beta of 0.64.
Several hedge funds have recently added to or reduced their stakes in the company. First Trust Advisors LP bought a new stake in shares of CytomX Therapeutics in the 1st quarter worth approximately $263,000. Strs Ohio grew its stake in shares of CytomX Therapeutics by 7.5% in the 2nd quarter. Strs Ohio now owns 59,900 shares of the biotechnology company’s stock worth $672,000 after buying an additional 4,200 shares during the last quarter. Aperio Group LLC purchased a new stake in shares of CytomX Therapeutics in the 2nd quarter worth approximately $70,000. DekaBank Deutsche Girozentrale increased its position in CytomX Therapeutics by 64.6% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 24,200 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 9,500 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. increased its position in CytomX Therapeutics by 2.8% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 687,833 shares of the biotechnology company’s stock valued at $7,684,000 after buying an additional 19,000 shares in the last quarter. Hedge funds and other institutional investors own 78.89% of the company’s stock.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Read More: Is a Roth IRA right for you?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.